Trillium Therapeutics News Headlines (NASDAQ:TRIL)

$0.39
0.00 (0.00 %)
(As of 09/23/2019 01:32 PM ET)
Today's Range
$0.39
Now: $0.39
$0.39
50-Day Range
$0.26
MA: $0.33
$0.4013
52-Week Range
$0.24
Now: $0.39
$6.30
Volume441 shs
Average Volume241,967 shs
Market Capitalization$10.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21

Headlines

Trillium Therapeutics (NASDAQ TRIL) News Headlines

Source:
DateHeadline
-$0.32 EPS Expected for Trillium Therapeutics Inc (NASDAQ:TRIL) This Quarter-$0.32 EPS Expected for Trillium Therapeutics Inc (NASDAQ:TRIL) This Quarter
www.americanbankingnews.com - September 3 at 6:09 PM
Global Bromodomain Containing Protein 2 Market 2019-2026 : F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Incyte CorpGlobal Bromodomain Containing Protein 2 Market 2019-2026 : F. Hoffmann-La Roche Ltd, Forma Therapeutics Inc, Incyte Corp
www.marketwatch.com - August 14 at 11:07 PM
Trillium Therapeutics Reports First Quarter 2019 Financial ResultsTrillium Therapeutics Reports First Quarter 2019 Financial Results
www.globenewswire.com - May 13 at 9:45 AM
Trillium Announces Management and Board Changes and Provides Corporate UpdateTrillium Announces Management and Board Changes and Provides Corporate Update
finance.yahoo.com - April 30 at 9:32 AM
Trillium Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyTrillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
finance.yahoo.com - April 11 at 10:58 AM
Trillium adds STING candidate to pipelineTrillium adds STING candidate to pipeline
seekingalpha.com - April 2 at 12:02 PM
Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist ProgramTrillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program
finance.yahoo.com - April 2 at 12:02 PM
Four Healthcare Stocks Picking Up Speed on WednesdayFour Healthcare Stocks Picking Up Speed on Wednesday
finance.yahoo.com - March 27 at 10:07 AM
Trillium Therapeutics IncTrillium Therapeutics Inc
www.bloomberg.com - March 19 at 9:58 AM
Trillium: 4Q Earnings SnapshotTrillium: 4Q Earnings Snapshot
finance.yahoo.com - March 11 at 6:22 PM
Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share UnitsTrillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
finance.yahoo.com - March 9 at 9:38 AM
IIROC Trading Halt - TRILIIROC Trading Halt - TRIL
www.bizjournals.com - February 22 at 10:46 AM
BRIEF-Trillium Announces Pricing Of $15 Mln Public Offering Of Common Share Units And Series II Non-Voting Convertible First Preferred Share UnitsBRIEF-Trillium Announces Pricing Of $15 Mln Public Offering Of Common Share Units And Series II Non-Voting Convertible First Preferred Share Units
www.msn.com - February 22 at 10:46 AM
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share UnitsTrillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
finance.yahoo.com - February 22 at 10:46 AM
Trillium down 39% after hours on equity offeringTrillium down 39% after hours on equity offering
seekingalpha.com - February 21 at 5:14 PM
Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual MeetingTrillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting
finance.yahoo.com - December 3 at 9:38 AM
Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating ResultsTrillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results
finance.yahoo.com - November 14 at 9:13 AM
Advanced Proteome Therapeutics Reports Progress on Collaboration with Noria PharmaceuticalsAdvanced Proteome Therapeutics Reports Progress on Collaboration with Noria Pharmaceuticals
globenewswire.com - October 15 at 9:14 AM
Trilliums TTI-621 shows encouraging action in early-stage studiesTrillium's TTI-621 shows encouraging action in early-stage studies
seekingalpha.com - September 28 at 9:25 AM
Trillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific ConferencesTrillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific Conferences
finance.yahoo.com - September 28 at 9:25 AM
Trillium Therapeutics to Present at Upcoming Investor ConferencesTrillium Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 27 at 9:27 AM
Trillium Therapeutics Announces Data Presentations at Upcoming Scientific MeetingsTrillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings
finance.yahoo.com - September 12 at 9:15 AM
Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceTrillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 30 at 9:42 AM
Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating ResultsTrillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results
finance.yahoo.com - August 8 at 9:42 AM
Trillium up 13% premarketTrillium up 13% premarket
seekingalpha.com - June 21 at 11:03 AM
Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus SupplementTrillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement
finance.yahoo.com - June 20 at 11:04 AM
Trillium Therapeutics Completes Amendment to SIRPaFc License AgreementTrillium Therapeutics Completes Amendment to SIRPaFc License Agreement
finance.yahoo.com - June 15 at 9:18 AM
Trillium Therapeutics (TRIL) Reports Dosing of First Patient With TTI-622, a Second Immune Checkpoint Inhibitor Targeting CD47Trillium Therapeutics (TRIL) Reports Dosing of First Patient With TTI-622, a Second Immune Checkpoint Inhibitor Targeting CD47
www.streetinsider.com - June 14 at 9:27 AM
Early-stage study commences for Trilliums blood cancer candidate TTI-622Early-stage study commences for Trillium's blood cancer candidate TTI-622
seekingalpha.com - June 14 at 9:27 AM
Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47
finance.yahoo.com - June 14 at 9:27 AM
Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical OfficerTrillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer
finance.yahoo.com - June 7 at 9:14 AM
Trillium Announces Voting Results From the Annual and Special Meeting of ShareholdersTrillium Announces Voting Results From the Annual and Special Meeting of Shareholders
finance.yahoo.com - June 5 at 9:13 AM
BRIEF-Trillium Therapeutics Files Prospectus Related To Offering Of 2.35 Mln Cos Common Shares By Selling ShareholdersBRIEF-Trillium Therapeutics Files Prospectus Related To Offering Of 2.35 Mln Co's Common Shares By Selling Shareholders
www.reuters.com - May 17 at 9:50 AM
Trillium: 1Q Earnings SnapshotTrillium: 1Q Earnings Snapshot
www.cnbc.com - May 11 at 10:35 AM
BRIEF-Trillium Therapeutics Reports Qtrly Earnings Per Share Of $0.65BRIEF-Trillium Therapeutics Reports Qtrly Earnings Per Share Of $0.65
www.reuters.com - May 11 at 10:35 AM
Trillium Therapeutics (TRIL) Provides Update on TTI-621 and TTI-622 ProgramsTrillium Therapeutics (TRIL) Provides Update on TTI-621 and TTI-622 Programs
www.streetinsider.com - April 10 at 10:00 AM
Trillium updates on TTI-621 and TTI-622 programsTrillium updates on TTI-621 and TTI-622 programs
seekingalpha.com - April 10 at 10:00 AM
BRIEF-Trillium Therapeutics Provides Update On Its Clinical ProgramsBRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs
www.reuters.com - April 10 at 10:00 AM
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical ProgramsTrillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs
finance.yahoo.com - April 10 at 10:00 AM
Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell LymphomaTrillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
finance.yahoo.com - March 20 at 9:49 AM
Trillium Therapeutics Reports Annual 2017 Financial and Operating ResultsTrillium Therapeutics Reports Annual 2017 Financial and Operating Results
finance.yahoo.com - March 9 at 10:12 AM
Blog Exposure - Trillium Announces Changes to Senior Management TeamBlog Exposure - Trillium Announces Changes to Senior Management Team
finance.yahoo.com - January 19 at 3:52 PM
Active-Investors: Blog Exposure - Trillium Announces Changes to Senior Management TeamActive-Investors: Blog Exposure - Trillium Announces Changes to Senior Management Team
www.finanznachrichten.de - January 19 at 10:16 AM
BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium TherapeuticsBRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics
www.reuters.com - December 8 at 3:42 PM
Trillium Announces Closing of Private Placement - BenzingaTrillium Announces Closing of Private Placement - Benzinga
www.benzinga.com - December 2 at 8:03 AM
Trillium Announces Closing of Private PlacementTrillium Announces Closing of Private Placement
finance.yahoo.com - December 2 at 8:03 AM
Trillium Therapeutics (TRIL) Says TTI-2341 EGFR Inhibitor Program Featured at SNO Meeting - StreetInsider.comTrillium Therapeutics (TRIL) Says TTI-2341 EGFR Inhibitor Program Featured at SNO Meeting - StreetInsider.com
www.streetinsider.com - November 20 at 11:23 AM
Trillium Therapeutics (TRIL) Reports $19.98M Private Placement - StreetInsider.comTrillium Therapeutics (TRIL) Reports $19.98M Private Placement - StreetInsider.com
www.streetinsider.com - November 15 at 4:55 PM
Is It Time To Buy Trillium Therapeutics Inc (TRIL)?Is It Time To Buy Trillium Therapeutics Inc (TRIL)?
finance.yahoo.com - November 15 at 4:55 PM
Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual MeetingTrillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting
finance.yahoo.com - November 14 at 11:35 AM
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Featured Article: What is a Special Dividend?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel